0000000000240335

AUTHOR

Franck Paganelli

showing 4 related works from this author

Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile

2020

Aim: to evaluate the impact of a nationwide lockdown in France on acute myocardial infarction (AMI) admissions, by patient characteristics and regional prevalence of the pandemic. Methods and Results: We collected data from 21 centres participating in the on-going FRENCHIE registry (NCT04050956), which collects data from all patients admitted for STEMI or NSTEMI within 48 hours of symptom onset. We compared weekly admissions in the 4 weeks preceding and the 4 weeks following institution of the lockdown. We observed a brutal 30% decrease in AMI admissions (24% for STEMI and 36% for NSTEMI, P=0.14) following institution of the lockdown, with similar trends according to gender (30% decrease in…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryFamily medicineHospital admissionmedicinePatient profilePatient characteristicsIn patientSymptom onsetbusinessRegulatory authoritySSRN Electronic Journal
researchProduct

Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy

2021

Optimal antithrombotic therapy after percutaneous coronary intervention (PCI) in patients on oral anticoagulants (OAC) remains a clinical conundrum. In fact, combining an OAC with dual antiplatelet therapy (triple antithrombotic therapy, TAT) increases the risk of bleeding. Clopidogrel is the only thienopyridine recommended in TAT patients. Whether its response plays a relevant role in this setting remains uncertain. We aimed to evaluate the level of platelet reactivity inhibition (PRI) achieved by oral TAT in Acute Coronary Syndrome (ACS) patients undergoing PCI and its relationship with outcomes. We performed a multicenter prospective observational study and assessed PRI by vasodilator-st…

platelet reactivityAcute coronary syndromemedicine.medical_specialtyThienopyridinetriple antithrombotic therapymedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyLoading doseArticleacute coronary syndromeVASP index03 medical and health sciences0302 clinical medicineInternal medicineAntithromboticClinical endpointMedicinecardiovascular diseases030212 general & internal medicineclopidogrelbusiness.industrylcsh:RPercutaneous coronary interventionGeneral Medicinemedicine.diseaseClopidogrelConventional PCICardiologybusinessmedicine.drugJournal of Clinical Medicine
researchProduct

Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in Fra…

2020

Background The COVID-19 pandemic has had a profound effect on general health care. We aimed to evaluate the effect of a nationwide lockdown in France on admissions to hospital for acute myocardial infarction, by patient characteristics and regional prevalence of the pandemic. Methods In this registry study, we collected data from 21 centres participating in the ongoing French Cohort of Myocardial Infarction Evaluation (FRENCHIE) registry, which collects data from all patients admitted for ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI) within 48 h of symptom onset. We analysed weekly hospital admissions over 8 weeks: the 4 weeks …

Malemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralMyocardial InfarctionRate ratio01 natural sciencesCohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicinePatient Admission[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsPrevalenceMedicineST segmentHumans030212 general & internal medicinePoisson regressionMyocardial infarctionRegistries0101 mathematicsPandemicsAgedAged 80 and overbusiness.industry010102 general mathematicsPublic Health Environmental and Occupational HealthCOVID-19ArticlesMiddle Agedmedicine.disease3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieEmergency medicineCohortsymbolsObservational studyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusinessCoronavirus InfectionsCohort study
researchProduct

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct